cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Cti Biopharma Corp
1 own
4 watching
Current Price
$9.05
$0
(0%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,183.26M
52-Week High
52-Week High
9.055
52-Week Low
52-Week Low
4.005
Average Volume
Average Volume
1.95M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,183.26M
icon52-Week High9.055
icon52-Week Low4.005
iconAverage Volume1.95M
iconDividend Yield--
iconP/E Ratio--
What does the Cti Biopharma Corp do?
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
Read More
How much money does Cti Biopharma Corp make?
News & Events about Cti Biopharma Corp.
PR Newswire
2 months ago
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SEATTLE, March 20, 2023 SEATTLE, March 20, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial...
Zolmax
2 months ago
StockNews.com upgraded shares of CTI BioPharma (NASDAQ:CTIC Get Rating) from a sell rating to a hold rating in a research report released on Tuesday . Several other equities analysts also recently issued reports on the stock. JMP Securities reissued a market outperform rating and set a $9.00 price ...
PR Newswire
3 months ago
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SEATTLE, Feb. 7, 2023 SEATTLE, Feb. 7, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized...
PR Newswire
4 months ago
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SEATTLE, Jan. 24, 2023 SEATTLE, Jan. 24, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an...
PR Newswire
6 months ago
Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope PR Newswire PALM BEACH, Fla., Dec. 1, 2022 FinancialNewsMedia.com News Commentary PALM BEACH, Fla., Dec. 1, 2022 /PRNewswire/ -- The...
Frequently Asked Questions
Frequently Asked Questions
What is Cti Biopharma Corp share price today?
plus_minus_icon
Can Indians buy Cti Biopharma Corp shares?
plus_minus_icon
How can I buy Cti Biopharma Corp shares from India?
plus_minus_icon
Can Fractional shares of Cti Biopharma Corp be purchased?
plus_minus_icon
What are the documents required to start investing in Cti Biopharma Corp stocks?
plus_minus_icon
What is today’s traded volume of Cti Biopharma Corp?
plus_minus_icon
What is today’s market capitalisation of Cti Biopharma Corp?
plus_minus_icon
What is the 52-Week High and Low Range of Cti Biopharma Corp?
plus_minus_icon
What percentage is Cti Biopharma Corp down from its 52-Week High?
plus_minus_icon
What percentage is Cti Biopharma Corp up from its 52-Week Low?
plus_minus_icon
Current Price
$9.05
$0
(0%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Kura Oncology Inc
Kura Oncology Inc
$13.20
$-0.30 (-2.22 %)
Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc
$9.54
$0.42 (4.61 %)
Vericel Corporation
Vericel Corporation
$32.93
$0.27 (0.83 %)
ADMA BIOLOGICS INC
ADMA BIOLOGICS INC
$4.05
$0.04 (1.00 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Kura Oncology Inc
Kura Oncology Inc
$13.20
$-0.30 (-2.22 %)
Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc
$9.54
$0.42 (4.61 %)
Vericel Corporation
Vericel Corporation
$32.93
$0.27 (0.83 %)
ADMA BIOLOGICS INC
ADMA BIOLOGICS INC
$4.05
$0.04 (1.00 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00